Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital

被引:47
|
作者
O'Sullivan, JM
Norman, AR
Cook, GJ
Fisher, C
Dearnaley, DP
机构
[1] Royal Marsden Hosp, Royal Marsden NHS Trust, Inst Canc Res, Acad Unit Radiotherapy & Clin Oncol, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden Hosp, Inst Canc Res, Dept Comp & Informat, Sutton SM2 5PT, Surrey, England
[3] Royal Marsden Hosp, Inst Canc Res, Dept Nucl Med, Sutton SM2 5PT, Surrey, England
[4] Royal Marsden Hosp, Inst Canc Res, Dept Histopathol, Sutton SM2 5PT, Surrey, England
关键词
radionuclide imaging; prostatic neoplasms; bone metastases; Gleason scoring;
D O I
10.1046/j.1464-410X.2003.04480.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To determine if it is possible to exclude staging bone scans in a greater proportion of patients if more consideration is given to T stage and Gleason score, as recent guidelines from the National Institute of Clinical Excellence state that routine staging bone scans for prostate cancer are unnecessary in patients with a prostate specific antigen level (PSA) of < 10 ng/mL and Gleason scores of < 8. We identified a cohort of consecutive patients with untreated prostate cancer who had a staging isotope bone scan between 1 January 1995 and 31 December 2000, who were not on hormone therapy, who had their PSA estimated within 30 days of the scan, and who had histologically confirmed prostate cancer on biopsy reviewed at the Royal Marsden. Data were analysed according to Gleason score, major Gleason grade, clinical T-stage and PSA level. In all, 420 patients were identified who fulfilled the criteria for inclusion; 67 scans (16%, 95% confidence interval, CI, 13-20%) were positive. Of the 187 scans taken in patients with a PSA level of less than or equal to 20 ng/mL, stage < T4 and Gleason < 8 (with major Gleason grade < 4), two (1%, 0.3-4%) were reported as positive, giving a negative predictive value of 99% (95% CI 98.5-99.5%) for these criteria for avoiding the need for staging bone scans. In 116 patients (28%) with Gleason score 7, of whom 28 (24%) had positive scans, there was a statistically significant association between positive scans and a major Gleason pattern of 4 compared with 3. Isotope bone scans are an unnecessary part of staging of prostate cancer if the PSA level is less than or equal to 20 ng/mL, stage < T4 and Gleason score < 8, and should be omitted unless the major Gleason pattern is 4. The present results suggest that by considering the Gleason score and T stage, a larger proportion of patients with prostate cancer than previously thought could avoid a staging bone scan.
引用
收藏
页码:685 / 689
页数:5
相关论文
共 50 条
  • [31] When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
    Yiwei Lin
    Qiqi Mao
    Bin Chen
    Liujiang Wang
    Ben Liu
    Xiangyi Zheng
    Liping Xie
    BMC Urology, 17
  • [32] When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
    Lin, Yiwei
    Mao, Qiqi
    Chen, Bin
    Wang, Liujiang
    Liu, Ben
    Zheng, Xiangyi
    Xie, Liping
    BMC UROLOGY, 2017, 17
  • [33] RESULTS OF EXTERNAL-BEAM RADIOTHERAPY IN DIFFERENTIATED THYROID-CARCINOMA - A RETROSPECTIVE STUDY FROM THE ROYAL-MARSDEN-HOSPITAL
    OCONNELL, MEA
    AHERN, RP
    HARMER, CL
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (06) : 733 - 739
  • [34] Assessment of bone health in patients with prostate cancer using cancer staging computed tomography
    Mototaka Sato
    Masafumi Kashii
    Atsuki Matsukawa
    Ryoya Mizuno
    Mai Akiyama
    Takashi Kamatani
    Satoshi Kamido
    Norichika Ueda
    Jiro Nakayama
    Norihide Tei
    Hideki Yoshikawa
    Osamu Miyake
    Journal of Bone and Mineral Metabolism, 2022, 40 : 648 - 656
  • [35] Assessment of bone health in patients with prostate cancer using cancer staging computed tomography
    Sato, Mototaka
    Kashii, Masafumi
    Matsukawa, Atsuki
    Mizuno, Ryoya
    Akiyama, Mai
    Kamatani, Takashi
    Kamido, Satoshi
    Ueda, Norichika
    Nakayama, Jiro
    Tei, Norihide
    Yoshikawa, Hideki
    Miyake, Osamu
    JOURNAL OF BONE AND MINERAL METABOLISM, 2022, 40 (04) : 648 - 656
  • [36] Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience
    Reid, A.
    Attard, G.
    Oommen, N. Babu
    Olmos, D.
    Fong, P.
    Molife, R.
    Dowsett, M.
    Lee, G.
    Molina, A.
    De-Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 12 - 12
  • [38] VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER
    Briganti, Alberto
    Picchio, Maria
    Gallina, Andrea
    Messa, Cristina
    Suardi, Nazareno
    Giovacchini, Giampiero
    Salonia, Andrea
    Fenari, Matteo
    Abdollah, Firas
    Gianolli, Luigi
    Zanni, Giuseppe
    Scattoni, Vincenzo
    Rigatti, Patrizio
    Fazio, Ferruccio
    Montorsi, Francesco
    JOURNAL OF UROLOGY, 2009, 181 (04): : 782 - 782
  • [39] Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases
    Ho, Christopher Chee Kong
    Seong, Poh Keat
    Zainuddin, Zulkifli Md
    Manaf, Mohd Rizal Abdul
    Parameswaran, Muhilan
    Razack, Azad H. A.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) : 3289 - 3292
  • [40] Computer-Delivered Cognitive Behaviour Therapy for Cancer Patients [CCBTCa]: Evaluation of a novel Royal Marsden Hospital Website
    Watson, M.
    Durey-Lee, V
    Bryant, S.
    Mohammed, K.
    Davolls, S.
    Edwards, L.
    PSYCHO-ONCOLOGY, 2013, 22 : 21 - 22